erythromycin has been researched along with voriconazole in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Ghahramani, P; Kleinermans, D; Layton, G; Nichols, D; Purkins, L; Wood, N | 1 |
| Chen, XP; Ouyang, DS; Shi, HY; Tan, ZR; Wu, WH; Yan, J; Yang, GP; Zhou, G; Zhu, WH | 1 |
| Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J | 1 |
| Chen, J; Chen, L; Guo, S; Lei, J; Xu, P; Xu, T; Yu, L; Yu, X; Zhou, X; Zhu, S | 1 |
1 review(s) available for erythromycin and voriconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for erythromycin and voriconazole
| Article | Year |
|---|---|
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Azithromycin; Drug Combinations; Drug Interactions; Erythromycin; Humans; Male; Pyrimidines; Triazoles; Voriconazole | 2003 |
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Topics: Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; China; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP2C19; Erythromycin; Humans; Male; Polymorphism, Single Nucleotide; Protein Synthesis Inhibitors; Pyrimidines; Triazoles; Voriconazole; Young Adult | 2010 |
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erythromycin; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Piperidines; Polymorphism, Single Nucleotide; Pyrazoles; Pyrimidines; Voriconazole | 2018 |
5 other study(ies) available for erythromycin and voriconazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Topics: Aminopyridines; Animals; Benzamides; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Female; Humans; Male; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Voriconazole | 2020 |